Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
CCX559 / Amgen
ACTRN12621001342808: A Study To Determine The Safety, Tolerability, Pharmacokinetics And Recommended Phase 2 Dose Of CCX559 In patients With Solid Tumors	Terminated	1	90			ChemoCentryx, Inc, ChemoCentryx, Inc	Neoplastic Disorder - Solid Tumors